Wedbush Lowers Day One Biopharmaceuticals Earnings Outlook for 2025 Wedbush analysts have trimmed their Q1 2025 earnings per share estimates for Day One Biopharmaceuticals, now expecting a loss of $0.45 per share, down from $0.43. Despite the revised outlook, the firm maintains an 'Outperform' rating and a $32 target price, reflecting continued confidence in the company's long-term prospects.12